Satudora Holdings Co Ltd

Satudora Holdings maintains a debt-to-equity ratio of 1.76, indicating a moderate reliance on debt financing, and a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company's return on equity (ROE) is 7.85%, which is below the typical benchmark for high-performing retailers, while its return on assets (ROA) is 1.66%, reflecting modest asset efficiency. The company's profitability is constrained by a gross margin of 25.59% and an operating margin of 1.24%, both of which are below the median for the Drug Retailers industry. The net income of 769 million JPY represents a thin margin of 0.77% of revenue, indicating pressure from competitive pricing and operational costs. Satudora's revenue is concentrated in Japan, with no disclosed international operations, and its business is primarily driven by retail segments. The company operates through a single disclosed segment, which is the retail of health and beauty products, pharmaceuticals, and daily necessities. This lack of diversification increases exposure to domestic economic and regulatory shifts. The company's revenue growth has been modest, with a recent actual revenue of 95.52 billion JPY, slightly below the reported revenue of 100.17 billion JPY. The outlook for the current fiscal year suggests a continuation of this trend, with no significant acceleration in revenue or profit expected in the near term. The risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk, as the company has not issued additional shares recently. The capital structure is supported by a relatively stable share count, with no dilution observed between basic and diluted shares. Recent filings and transcripts indicate no major strategic shifts or capital-raising activities. The company's focus remains on maintaining its retail operations and managing debt levels. No significant new product launches or market expansions were disclosed in the latest reports.